2000: Don Listwin’s mother, Grace Listwin, misdiagnosed with bladder infection
2001: Grace Listwin dies of late-stage ovarian cancer due to detection of her cancer at a late stage
2002: Ovarian cancer biomarker work for Dr. Nicole Urban funded by Listwin Family Foundation at the Fred Hutch Cancer Research Center (FHCRC) in Seattle
2003: Center of Excellence for early cancer detection established by Dr. Lee Hartwell at FHCRC focusing on cancer biomarkers
2003: First Canary science team formed—ovarian cancer
2004: Canary Foundation formed by Don Listwin
2005: Second Canary science team formed—pancreatic cancer
2005: First annual Scientific Symposium
2006: Discovery of gene mutation in pancreatic cancer
2006: Partnership with Canadian British Columbia Cancer Agency to build antibodies and assays for blood biomarkers
2007: Two more Canary science teams formed—prostate and lung
2007: Microbubble-based molecular imaging studies
2008: Prostate Active Surveillance Study (PASS) enrolls first patients
2008: Canary ovarian team conducts preclinical validation of ovarian biomarker HE4
2009: Founded Canary Center at Stanford with Stanford School of Medicine and Stanford Cancer Institute
2009: Canary ovarian team launches Novel Markers Trial
2009: Magneto-nano sensor developed to detect biomarkers—10,000 times more sensitive than existing tests
2009: Never Smokers Lung Cancer Study launches
2009: Don Listwin named to National Cancer Institute Board of Scientific Advisors
2010: Lung cancer imaging trial begins at Stanford
2010: Stanford team builds photoacoustic device for prostate cancer (begins testing in 2011)
2010: Parag Mallick & Sharon Pitteri hired—first full-time faculty at Stanford dedicated 100% to early cancer detection
2011: Gene fusion discovered for ovarian cancer
2011: Canary pancreatic cancer team demonstrates microbubble imaging to below 1 mm in size
2011: Canary lung cancer team discovers novel biomarker that defines patients as high-risk
2012: Breast Cancer Program launched
2012: Stanford Cancer Institute Awards Canary Foundation with Spirit of Hope Award
2013: Stanford moves Canary Center to Stanford’s Technology and Innovation Park—2x lab space
2013: Genomic Health partners with PASS team to work on detection test for prostate cancer
2013: Microbubble clinical trials in ovarian and breast cancer begin in Rome
2014: FDA approves ultrasound using microbubble—trials begin for men with prostate cancer at Stanford
2014: Canary prostate cancer team—PASS wins competitive NCI award
2014: Partnership with MD Anderson to build national lung cancer screening trial
2014: Clinical trials begin in partnership with El Camino Hospital for pancreatic early cancer detection
2014: Canary Center recruits Utkan Demirci from Harvard/MIT with expertise in biomedical microfluidic technology platforms
2014: CRUK launches early cancer detection initiatives in UK
2014: OHSU launches billion-dollar early detection initiative
2015: Tom Soh recruited from UCSB—focusing on portable, rapid, and sensitive diagnostic platforms
2015: Canary develops Canary Quantum Cloud to give researchers access to new machine-learning platform
2016: Canary Pancreas Team discovers new biomarker candidate for cancer imaging
2017: Lung cancer biomarker discovered by Canary researchers attracts interest from multiple academic institutions and industry partners who obtain licensing to do further testing
2018: Canary forges international collaborative partnerships with the University of Calgary and University of Cambridge by funding a series of early detection projects with researchers from both institutions
2018: Canary partners with BRCA Foundation to launch new ovarian cancer initiative that examines the link between high-risk factors and early detection
2019: Launch of multi-institutional Canary High Grade Serous Ovarian Initiative
2019: Microbubble technology approved for breast cancer
2019: Microbubble approved for pancreatic cancer
2019: Completion of first Early Cancer Detection Initiative pilot awards with University of Calgary
2019: Launch of ACED Alliance – The International Alliance for Cancer Early Detection: partnership between Cancer Research UK, the Canary Center at Stanford University, the University of Cambridge, the Knight Cancer Institute at OHSU, University College London and the University of Manchester
2019: First jointly funded Early Cancer Detection Conference hosted at Stanford through the Canary Center at Stanford-Knight Cancer Institute at OHSU-Cancer Research UK collaboration
2020: In Loving Memory Sanjiv Sam Gambhir, MD, PhD (November 23, 1962 – July 18, 2020) – Read our remembrances of Sam
2021: Milestone enrollment of 2000 men in the Canary Prostate Active Surveillance Study (PASS)
2022: International Early Detection of Cancer Conference returns to in-person format after 2 years of virtual meetings
2022: Canary partnered with Gray Foundation on multiomic analysis of benign fallopian tube tissue to identify early molecular events leading to BRCA-associated High Grade Serous Ovarian Cancer
2023: Launch of PATROL: Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease
2023: Prostate Active Surveillance gene expression profiling study with Veracyte/Decipher begins
2023: Pilot study shows pancreas and lesions are visible in the majority of patients using inexpensive Point of Care Ultrasound
Future Goals: Canary marker remains among the four-marker panel showing mortality reduction benefit for lung cancer
Future Goals: First patients imaged with contrast using Point of Care Ultrasound
Future Goals: Manufacturing pipeline for microbubbles for early detection established
Future Goals: Consensus reached on best practices for Active Surveillance for prostate cancer
Future Goals: Multiomic analysis of BRCA vs non-BRCA benign fallopian tubes complete dataset reported
Future Goals: Geospatial characterization of fallopian tube precursors of ovarian cancer reported